Vaccines for covid-19 patients

If you want to see all comparisons, please click here

ChAdOx1 vs MenACWY

The Evidence profile and Summary of Findings table were updated on January 25th, 2021.

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots

Evidence profile

Summary of findings


Trial Comparisons Design Participants Sample size Overall risk of bias
Primary outcome
Full description
Treatment 1 Treatment 2
NCT04324606; ISRCTN15281137; EudraCT 2020-001072-15
University of Oxford/AstraZeneca
Folegatti PM (COV001), Lancet, 2020

Full text

Barrett JR, Nature medicine, 2020
Full text

Ewer KJ, Nature medicine, 2020
Full text

Commentary
Commentary
ChAdOx1 MenACWY RCT
Phase 1/2
Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK N=1077
Low
Details

Full description

NCT04400838
University of Oxford/AstraZeneca
Voysey M (COV002), Lancet, 2020
Full text
Commentary
ChAdOx1 LD/SD 1/2 doses MenACWY RCT
Phase 2/3
Healthy adults in 18 centers in the UK N=7548
Some concerns
Details
Full description
ChAdOx1 SD/SD 1/2 doses MenACWY
ISRCTN89951424
University of Oxford/AstraZeneca
Voysey M (COV003), Lancet, 2020

Full text
Commentary
ChAdOx1 SD/SD MenACWY/saline RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=4088
Some concerns
Details

Full description

NCT04444674
University of Oxford/AstraZeneca
Voysey M (COV005), Lancet, 2020

Full text
Commentary
ChAdOx1 std 2 doses Saline RCT
Phase 1/2
Healthy adults from four studies in multiple centres in Brazil, South Africa, and the UK N=2013

Details

Full description

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.